Meningococcal ACWY conjugate vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Meningitis
Conditions
Bacterial Meningitis
Trial Timeline
Aug 1, 2011 → Jan 1, 2012
NCT ID
NCT01410474About Meningococcal ACWY conjugate vaccine
Meningococcal ACWY conjugate vaccine is a phase 3 stage product being developed by Novartis for Bacterial Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01410474. Target conditions include Bacterial Meningitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01547715 | Phase 3 | Completed |
| NCT01410474 | Phase 3 | Completed |
Competing Products
20 competing products in Bacterial Meningitis